CompletedPhase 1psilocybin
Effects of Psilocybin in Advanced-Stage Cancer Patients With Anxiety
Sponsored by Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
NCT ID
NCT00302744
Target Enrollment
12 participants
Start Date
2004-04
Est. Completion
2008-12
About This Study
Psychiatric Research Study For Cancer Patients The Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center is conducting a study designed to measure the effectiveness of the novel psychoactive medication psilocybin on the reduction of anxiety, depression, and physical pain.
Conditions Studied
Interventions
- •Psilocybin (drug)
- •Niacin
- •MRI
Eligibility
Age:18 Years - 70 Years
Healthy Volunteers:No
View full eligibility criteria
Inclusion Criteria: * Have advanced-stage cancer and anxiety. * Be between the ages of 18 - 70. Note: The location for the two treatment sessions is Los Angeles, California. Treatment sessions are scheduled three to six weeks apart, and they include one overnight hospital stay both times. Exclusion Criteria: * Not have cancer that affects the central nervous system or brain function. * Have no history of major psychiatric disorder. * Have no kidney disease, abnormal liver functions, epilepsy, or cardiovascular disease, including untreated hypertension. * Not be taking insulin, oral hypoglycemic, anti-seizure, or cardiovascular medications (except anti-hypertensive drugs). * May take PRN benzodiazepines up to 3 days before the session. * No Prozac for the previous 5 weeks. * No medications the day of and the day after treatment sessions, except may take ongoing adjuvant chemotherapy as prescribed, prescribed or over-the-counter non-narcotic pain medication at any time, and narcotic pain medications up to eight hours before administration of psilocybin and six hours after administration. * No alcohol consumption the day before, the day of, and the day after a session. * Female subjects of childbearing potential must have a negative pregnancy test and agree to use an effective form of birth control.
Study Locations (1)
Harbor-UCLA Medical Center
Torrance, California, United States